TrialCancer science2021

Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.

Takashi Seto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.